

UNITED STATES PATENT AND TRADEMARK OFFICE

In re Debiovision Inc.  
Request for Patent Term Extension  
U.S. Patent No. 4,650,787


:  
: **ORDER GRANTING**  
: **INTERIM EXTENSION**

On March 24, 2008, Debiovision Inc., an agent of the Administrators of the Tulane Educational Fund of New Orleans, Louisiana, patent owner, timely filed an application under 35 U.S.C. § 156(d)(5) for a fourth interim extension of the term of U.S. Patent No. 4,650,787. The patent claims the active ingredient vapreotide acetate in the drug product Sanvar®. The application indicates that a New Drug Application for the human drug product Sanvar® (vapreotide acetate) has been filed and is currently undergoing regulatory review before the Food and Drug Administration for permission to market or use the product commercially.

Review of the application indicates that except for permission to market or use the product commercially, the subject patent would be eligible for an extension of the patent term under 35 U.S.C. § 156, and that the patent should be extended for an additional year as required by 35 U.S.C. § 156(d)(5)(B). Because it is apparent that the regulatory review period will continue beyond the extended expiration date of the patent (April 25, 2008), interim extension of the patent term under 35 U.S.C. § 156(d)(5) is appropriate.

An interim extension under 35 U.S.C. § 156(d)(5) of the term of U.S. Patent No. 4,650,787 is granted for a period of one year from the extended expiration date of the patent, i.e., until April 25, 2009.

4/09/08  
Date

  
\_\_\_\_\_  
Jon W. Dudas  
Under Secretary of Commerce for Intellectual Property and  
Director of the United States Patent and Trademark Office